We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
+18.46%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$29.7M
(-16%)
Cap. Flow
+$9.23M
Cap. Flow
% of AUM
6.1%
Top 10 Holdings %
Top 10 Hldgs %
42.62%
Holding
71
New
15
Increased
21
Reduced
14
Closed
14
Avg Time Held Equity + Options
2.3
quarters
Top 10 Avg Time Held Equity + Options
0.5
quarters
Top 20 Avg Time Held Equity + Options
2.6
quarters
Avg Time Held Equity only
2.4
quarters
Top 10 Avg Time Held Equity only
0.9
quarters
Top 20 Avg Time Held Equity only
2.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$4.74M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$3.78M |
| 3 |
Gilead Sciences
GILD
|
+$3.06M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.72M |
| 5 |
Merck
MRK
|
+$2.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bio-Techne
TECH
|
+$4.35M |
| 2 |
CPHD
Cepheid Inc
CPHD
|
+$4.07M |
| 3 |
AstraZeneca
AZN
|
+$2.85M |
| 4 |
Biogen
BIIB
|
+$2.01M |
| 5 |
Mettler-Toledo International
MTD
|
+$1.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.26% |
| 2 | Miscellaneous | 14.74% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
iShares Biotechnology ETF
IBB
$10.5B
| $10.7M | 7.06% |
94,800
+34,800
| +58% | +$3.78M |
2015 Q3
1 quarter
|
|
2
Alkermes
ALKS
$6.79B
| $6.94M | 4.58% |
87,415
+551
| +0.6% | +$38.6K |
2014 Q4
4 quarters
|
|
3
Ionis Pharmaceuticals
IONS
$7.32B
| $6.34M | 4.19% |
102,459
+1,058
| +1% | +$57.1K |
2014 Q4
4 quarters
|
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.29M | 4.15% |
32,969
-52
| -0.2% | -$9.08K |
2014 Q4
4 quarters
|
|
5
Nektar Therapeutics
NKTR
$1.37B
| $5.87M | 3.88% |
23,239
-6,378
| -22% | -$1.31M |
2014 Q4
4 quarters
|
|
6
Regeneron Pharmaceuticals
REGN
$78.9B
| $5.82M | 3.84% |
10,714
+87
| +0.8% | +$47.1K |
2014 Q4
4 quarters
|
|
|
7
Amgen
AMGN
$224B
| $5.81M | 3.84% |
35,773
+30,147
| +536% | +$4.74M |
2014 Q4
4 quarters
|
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $5.74M | 3.79% |
47,956
+819
| +2% | +$94.8K |
2014 Q4
4 quarters
|
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.7M | 3.77% |
127,088
+2,530
| +2% | +$105K |
2014 Q4
4 quarters
|
|
|
10
Bristol-Myers Squibb
BMY
$117B
| $5.3M | 3.5% |
77,100
+41,100
| +114% | +$2.72M |
2015 Q3
1 quarter
|
|
11
Vertex Pharmaceuticals
VRTX
$129B
| $5.24M | 3.46% |
41,662
+786
| +2% | +$94.9K |
2014 Q4
4 quarters
|
|
12
Incyte
INCY
$22.8B
| $5.21M | 3.44% |
48,045
+645
| +1% | +$71.9K |
2014 Q4
4 quarters
|
|
|
13
Merck
MRK
$358B
| $4.75M | 3.14% |
94,320
+51,352
| +120% | +$2.59M |
2015 Q3
1 quarter
|
|
14
Alnylam Pharmaceuticals
ALNY
$30.7B
| $4.73M | 3.12% |
50,222
+1,774
| +4% | +$164K |
2014 Q4
4 quarters
|
|
15
BioMarin Pharmaceuticals
BMRN
$10.7B
| $4.6M | 3.04% |
43,870
+1,858
| +4% | +$194K |
2014 Q4
4 quarters
|
|
|
QGENF
16
DELISTED
QIAGEN NV
QGENF
| $4.42M | 2.92% |
160,000
| – | – |
2014 Q4
4 quarters
|
|
|
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
| $4.41M | 2.92% |
91,310
-27,062
| -23% | -$1.17M |
2014 Q4
4 quarters
|
|
18
Illumina
ILMN
$40.8B
| $4.35M | 2.87% |
23,277
-5,850
| -20% | -$944K |
2014 Q4
4 quarters
|
|
|
19
Gilead Sciences
GILD
$186B
| $3.41M | 2.25% |
33,700
+29,377
| +680% | +$3.06M |
2014 Q4
4 quarters
|
|
|
20
Mettler-Toledo International
MTD
$31.2B
| $3.29M | 2.17% |
9,700
-5,500
| -36% | -$1.76M |
2014 Q4
4 quarters
|
|
|
21
Biogen
BIIB
$34.6B
| $3.21M | 2.12% |
10,482
-6,985
| -40% | -$2.01M |
2014 Q4
4 quarters
|
|
|
ADMS
22
DELISTED
Adamas Pharmaceuticals
ADMS
| $2.27M | 1.5% |
+80,000
| New | +$1.35M |
2015 Q4
0 quarters
|
|
23
Agios Pharmaceuticals
AGIO
$1.86B
| $2.21M | 1.46% |
34,000
-12,000
| -26% | -$787K |
2015 Q3
1 quarter
|
|
|
EPZM
24
DELISTED
Epizyme, Inc
EPZM
| $2.17M | 1.44% |
135,627
+89,548
| +194% | +$1.33M |
2014 Q4
4 quarters
|
|
25
DELISTED
Hologic
HOLX
| $1.86M | 1.23% |
48,000
| – | – |
2014 Q4
4 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q4 2015 Portfolio in Review
As of Q4 2015, Opus Point Partners Management held 71 positions worth $151M, down 16% from $181M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Opus Point Partners Management deployed $9.23M of net new capital in Q4 2015, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was AstraZeneca, an estimated $2.85M trimmed.
- Opus Point Partners Management's largest Q4 2015 buy was Loxo Oncology, Inc: 60,000 shares worth $1.71M.
- Opus Point Partners Management added most to Amgen in Q4 2015, an estimated $4.74M increase.
- Opus Point Partners Management's biggest Q4 2015 reduction was AstraZeneca, cutting an estimated $2.85M.
- Opus Point Partners Management fully exited Bio-Techne in Q4 2015, selling an estimated $4.35M.
- Opus Point Partners Management's ten largest holdings make up 43% of its $151M portfolio in Q4 2015.
- Opus Point Partners Management opened 15 new positions and closed 14 in Q4 2015.
- Opus Point Partners Management's portfolio value fell 16% quarter-over-quarter to $151M.
Based on Opus Point Partners Management's 13F filing for Q4 2015, filed 16 Feb 2016.